Posted by Michael Wonder on 22 Oct 2020
Will HIRA resume talk to grant benefits for anti-diabetic combo drugs?
22 October 2020 - Three makers of SGLT-2 inhibiting anti-diabetic drugs said they would seek changes in approval conditions to allow their drugs to be used in combination with DPP-4 inhibitors in November.
The move draws attention to whether the state health insurance review agency will resume the discussion to approve insurance benefits for combo drugs mixing SGLT-2 inhibitors and DPP-4 inhibitors.
AstraZeneca, Boehringer Ingelheim, and MSD said they would apply for approval condition changes for SGLT-2 inhibitors as early as 3 November.
